Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8293070 | 1.00 | ALDH1A1 (0.42) | ALDH1A1ALOX15KMT2AMEN1MAPT | |
| SCHEMBL13232748 | 1.00 | ALDH1A1 (0.42) | ALDH1A1ALOX15KMT2AMEN1MAPT | |
| SCHEMBL8293540 | 0.83 | MEN1 (0.41) | ALDH1A1KMT2AMEN1MAPTLMNA | |
| SCHEMBL2800995 | 0.83 | LMNA (0.45) | ALDH1A1ALOX15KMT2AMEN1MAPT | |
| SCHEMBL2799190 | 0.83 | MEN1 (0.41) | ALDH1A1KMT2AMEN1MAPTLMNA | |
| SCHEMBL8294637 | 0.83 | LMNA (0.45) | ALDH1A1ALOX15KMT2AMEN1MAPT | |
| SCHEMBL13232746 | 0.81 | ALOX15 (0.46) | ALDH1A1ALOX15KMT2AMEN1MAPT | |
| SCHEMBL13232787 | 0.80 | TSHR (0.40) | KMT2AMEN1LMNATSHRKDM4E | |
| SCHEMBL14992838 | 0.77 | LMNA (0.46) | ALDH1A1ALOX15KMT2AMEN1MAPT | |
| SCHEMBL13232745 | 0.77 | LMNA (0.46) | ALDH1A1ALOX15KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753714-A4 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS INC (US) | 2007-10-17 | — | — | EP | claimed |
| EP-1753714-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | Renovis, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| WO-2005079270-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | RENOVIS, INC. | 2005-08-18 | — | — | US | claimed |
| US-20100168112-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | RENOVIS, INC. | 2010-07-01 | — | — | US | disclosed |
| CN-101123959-A | Aryl, heteroaryl and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions thereof for the treatment of human diseases | RENOVIS INC (US) | 2008-02-13 | — | — | CN | disclosed |
| US-20070275932-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | RENOVIS, INC. | 2007-11-29 | — | — | US | disclosed |
| EP-1753714-A4 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS INC (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1753714-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | Renovis, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1660011-A2 | ARYL, HETEROAROMATIC AND BICYCLIC ARYL NITRONE COMPOUNDS, PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | Renovis, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005079270-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | RENOVIS, INC. | 2005-08-18 | — | — | US | disclosed |
| US-20050059638-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | RENOVIS, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005016272-A2 | ARYL, HETEROAROMATIC AND BICYCLIC ARYL NITRONE COMPOUNDS, PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | RENOVIS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-6140356-A | Opthalmic pharmaceutical compositions comprising a nitrone compound and methods for treating ocular inflammation using such compositions | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-5972977-A | ALPHA-(4-PYRIDYL 1-OXIDE)-N-HYDROCARBYLNITRON USEFUL FOR TREATING EYE INFLAMMATION CONDITION SUCH AS UVEITIS | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-10-26 | — | — | US | disclosed |
| CN-1219130-A | Composition comprising a nitrone compound for use in treating ocular inflammation | CENTAUR PHARMACEUTICAL INC (US) | 1999-06-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275932-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | AHR, NAT1, ARNT | ALDH1A1 487/4885ALOX15 205/4885KMT2A 2587/4885 |
| US-20050059638-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | AHR, NAT1, ARNT | ALDH1A1 487/4885ALOX15 205/4885KMT2A 2587/4885 |
| US-20100168112-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | CXCR2, CCL5, CCL2 | ALDH1A1 226/4885ALOX15 140/4885KMT2A 4071/4885 |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | CXCR2, CCL5, CCL2 | ALDH1A1 226/4885ALOX15 140/4885KMT2A 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.